Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) |
---|---|
Information provided by: | National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) |
ClinicalTrials.gov Identifier: | NCT00000433 |
The Division of Rheumatology at University of California San Francisco is conducting a research study on the treatment of ankylosing spondylitis (AS) with a new therapy currently used for people with other forms of arthritis. The drug, called Enbrel (or etanercept), is a protein that is given twice weekly by injection underneath the skin. It blocks the action of tumor necrosis factor-alpha (TNF-alpha), a substance that may be involved in AS, rheumatoid arthritis, and other inflammatory conditions. We will randomly assign patients to receive either the drug or a placebo (inactive treatment) for 4 months. The results we will monitor include morning stiffness, spinal mobility, activities of daily life, and safety of the drug.
Condition | Intervention | Phase |
---|---|---|
Spondylitis, Ankylosing |
Drug: Anti-Tumor Necrosis Factor |
Phase II |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Double-Blind, Placebo Control, Single Group Assignment, Efficacy Study |
Official Title: | Anti-Tumor Necrosis Factor (TNFR:Fc) in Ankylosing Spondylitis |
Estimated Enrollment: | 42 |
Study Start Date: | October 1999 |
Estimated Study Completion Date: | March 2002 |
In this Phase II clinical trial we will use tumor necrosis factor receptor p75 fusion protein (TNFR:Fc, or etanercept) to treat patients with ankylosing spondylitis (AS). TNFR:Fc is an antagonist of tumor necrosis factor (TNF), a cytokine that researchers have shown to play a possible role in disease pathogenesis of ankylosing spondylitis, rheumatoid arthritis, and vasculitis, as well as other inflammatory conditions.
TNFR:Fc consists of two molecules of the extracellular portion of the p75 receptor, each consisting of 235 amino acids. The two receptors are fused to the Fc portion of human IgG1, which consists of 232 amino acids. The gene fragments encoding the truncated TNFR and the Fc portion of human IgG1 are expressed in a Chinese hamster ovary cell line.
Recent observations from animal and human studies suggest that tumor necrosis factor-alpha (TNF-alpha) may play a role in disease activity in AS and other seronegative spondyloarthropathies. This study aims to test the efficacy of TNFR:Fc used in conjunction with standard medications in the treatment of AS. We will give patients either 25mg of TNFR:Fc or placebo subcutaneously twice a week for 4 months. Outcome measures will include measures of function, pain, morning stiffness, patient global assessment, and swollen joint count, as well as safety measures.
Ages Eligible for Study: | 18 Years to 80 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
United States, California | |
UCSF-Clinical Trials Center | |
San Francisco, California, United States, 94143-0792 |
Principal Investigator: | John C. Davis, MD, MPH | Division of Rheumatology, University of California - San Francisco Department of Medicine |
Study ID Numbers: | N01 AR92244, NIAMS-043 |
Study First Received: | January 18, 2000 |
Last Updated: | January 2, 2007 |
ClinicalTrials.gov Identifier: | NCT00000433 |
Health Authority: | United States: Federal Government |
Spondylitis Etanercept ENBREL Tumor necrosis factor-alpha |
Spinal Diseases Necrosis Musculoskeletal Diseases Spondylarthropathy Arthritis Joint Diseases |
Spondylitis, Ankylosing Spondylarthritis Bone Diseases Spondylitis Ankylosis Spondylarthropathies |
Pathologic Processes Infection Bone Diseases, Infectious |